Human Genome Epidemiology Literature Finder
Records 1 - 11 (of 11 Records) |
Query Trace: Recurrence and CYP3A5[original query] |
---|
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast cancer research : BCR 2007 9 (1): R7. Wegman Pia, Elingarami Sauli, Carstensen John, Stål Olle, Nordenskjöld Bo, Wingren St |
Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast cancer research : BCR 2010 12 (3): R26. Gor Priya P, Su H Irene, Gray Robert J, Gimotty Phyllis A, Horn Michelle, Aplenc Richard, Vaughan William P, Tallman Martin S, Rebbeck Timothy R, DeMichele Ange |
Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen. Pharmacogenomics and personalized medicine 2013 6 93-8. Sensorn Insee, Sirachainan Ekaphop, Chamnanphon Montri, Pasomsub Ekawat, Trachu Narumol, Supavilai Porntip, Sukasem Chonlaphat, Pinthong Daraw |
Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients. PloS one 2013 8 (7): e70183. Fernández-Santander Ana, Gaibar María, Novillo Apolonia, Romero-Lorca Alicia, Rubio Margarita, Chicharro Luis Miguel, Tejerina Armando, Bandrés Fernan |
Immunological aspects in late phase of living donor liver transplant patients: usefulness of monitoring peripheral blood CD4+ adenosine triphosphate activity. Clinical & developmental immunology 2013 2013 982163. Mizuno Shugo, Muraki Yuichi, Nakatani Kaname, Tanemura Akihiro, Kuriyama Naohisa, Ohsawa Ichiro, Azumi Yoshinori, Kishiwada Masashi, Usui Masanobu, Sakurai Hiroyuki, Tabata Masami, Yamamoto Norihiko, Yamada Tomomi, Shiraki Katsuya, Takei Yoshiyuki, Nobori Tsutomu, Okuda Masahiro, Isaji Shu |
Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary intervention. International journal of clinical and experimental medicine 2015 8 (6): 9266-74. Chen Yu, Huang Xiaohong, Tang Yong, Xie Yuquan, Zhang Yach |
Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients. Transplantation 2016 Oct 100 (10): 2129-2137. Debette-Gratien Marilyne, Woillard Jean-Baptiste, Picard Nicolas, Sebagh Mylène, Loustaud-Ratti Véronique, Sautereau Denis, Samuel Didier, Marquet Pier |
Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome. BMC pharmacology & toxicology 2018 Apr 19 (1): 14. Li Min, Xu Min, Liu Wei, Gao X |
Impact of CYP3A4/5 and ABCB1 polymorphisms on tacrolimus exposure and response in pediatric primary nephrotic syndrome. Pharmacogenomics 2019 10 20 (15): 1071-1083. Huang Lingfei, Wang Junyan, Yang Jufei, Zhang Huifen, Ni Yinghua, Zhu Zhengyi, Wang Huijuan, Gao Peng, Wu Yuanyuan, Mao Jianhua, Fang L |
Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin. Acta oncologica (Stockholm, Sweden) 2020 5 59 (9): 1009-1015. Ahern Thomas P, Damkier Per, Feddersen Søren, Kjærsgaard Anders, Lash Timothy L, Hamilton-Dutoit Stephen, Lythjohan Cathrine Bredal, Ejlertsen Bent, Christiansen Peer M, Cronin-Fenton Deirdre |
[Effect of MDR1 and CYP3A5 gene polymorphisms on outcomes of patients receiving imatinib treatment for chronic myeloid leukemia]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2020 11 38 (1): 34-41. He Ying, Zao Xiumei, Wei Xueh |
- Page last reviewed:Feb 1, 2024
- Page last updated:Mar 25, 2024
- Content source: